Abstract
Transplantation with unrelated umbilical cord blood (UCB) is marked by delayed hematologic recovery. This report summarizes two adults with chronic myelogenous leukemia (CML), who received myeloablative conditioning followed by infusion of a non-expanded single UCB graft. These CML patients were enrolled in a clinical trial incorporating concomitant in vivo administration of stem cell factor (R-MetHuSCF) and filgrastim from day of UCB infusion until attained hematopoietic recovery. Each patient engrafted fully with donor UCB, with days to absolute neutrophil count (ANC) >500/microl being 13 and 29 days, respectively. Both patients remain in cytogenetic remission at 28 months follow-up. 'In vivo UCB expansion' with administration of concomitant R-MetHuSCF and filgrastim may facilitate prompt hematologic engraftment.
Publication types
-
Case Reports
-
Clinical Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Cord Blood Stem Cell Transplantation / adverse effects
-
Cord Blood Stem Cell Transplantation / methods*
-
Drug Therapy, Combination
-
Filgrastim
-
Graft Survival / drug effects
-
Granulocyte Colony-Stimulating Factor / administration & dosage*
-
Hematopoiesis / drug effects*
-
Histocompatibility
-
Histocompatibility Testing
-
Humans
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy
-
Male
-
Middle Aged
-
Myeloablative Agonists / therapeutic use
-
Recombinant Proteins
-
Stem Cell Factor / administration & dosage*
-
Stem Cell Factor / analogs & derivatives*
-
Transplantation Conditioning / methods
-
Transplantation, Homologous / methods
-
Treatment Outcome
Substances
-
Myeloablative Agonists
-
Recombinant Proteins
-
Stem Cell Factor
-
Granulocyte Colony-Stimulating Factor
-
Filgrastim
-
ancestim